Appareil Digestif PACHA 01 Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases - A Randomized Phase II/III Trial Saint-Cloud
Gynécologie - Ovaires YO39523 A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Saint-Cloud
Sein métastatique RH+ CONTESSA - ODO-TE-B301 Randomized, Phase 3 Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane Saint-Cloud ETIENNE BRAIN
Appareil Digestif EPIC 1511 Impact of Early Palliative Care on Overall Survival of Patients With Metastatic Upper Gastrointestinal Cancers, Treated With First-line Chemotherapy: a Randomized Phase III Trial. Saint-Cloud ELISABETH LUCCHI
Sarcomes STRASS 2 - ETUDE 1809-STBSG A randomized phase III study of neoadjuvant chemotherapy;followed by surgery versus surgery alone for patients with;High Risk RetroPeritoneal Sarcoma (STRASS 2) Paris SYLVIE BONVALOT
Prostate TEMPOS (GETUG P14) Erectile Dysfunction in Good Prognosis Prostate Cancer: a Phase III Medico-economic Study Comparing Brachytherapy to Stereotactic Body Radiotherapy Paris, Saint-Cloud
Sein métastatique RH+ AMBRE OPEN-LABEL, RANDOMIZED, MULTICENTER, PHASE III STUDY, COMPARING;STANDARD CHEMOTHERAPY TO ENDOCRINE THERAPY + ABEMACICLIB;COMBINATION AS INITIAL METASTATIC TREATMENT AMONG PATIENTS WITH;VISCERAL METASTASIS OF ER+ HER2- BREAST CANCER, HIGH BURDEN;DISEASE Paris, Saint-Cloud FRANCOIS-CLEMENT BIDARD, FRANCOIS-CLEMENT BIDARD
Prostate PRESTO (GETUG-AFU 36) Prostate-cancer treatment using stereotactic radiotherapy for oligometastases;ablation in hormone-sensitive patients À a GETUG-AFU phase III randomized controlled trial Paris
Gynécologie - Ovaires MIRASOL MIRASOL: A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression. Saint-Cloud